Aquestive Therapeutics (AQST) Upgraded to “Hold” by Zacks Investment Research

Zacks Investment Research upgraded shares of Aquestive Therapeutics (NASDAQ:AQST) from a sell rating to a hold rating in a research note released on Thursday morning.

According to Zacks, “Aquestive Therapeutics, Inc. is a specialty pharmaceutical company. It commercializes medicines to solve critical health care problems as well as engages on late-stage proprietary product pipeline which focuses on the treatment of diseases of central nervous system. Aquestive Therapeutics, Inc. is based in NJ, United States. “

Several other analysts have also issued reports on AQST. Wedbush assumed coverage on shares of Aquestive Therapeutics in a research report on Wednesday, September 12th. They issued an outperform rating and a $33.00 price target on the stock. Royal Bank of Canada set a $24.00 price target on shares of Aquestive Therapeutics and gave the stock a buy rating in a research note on Wednesday, November 7th. Finally, Lake Street Capital initiated coverage on shares of Aquestive Therapeutics in a research note on Thursday, January 3rd. They issued a buy rating and a $14.00 price target for the company. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. The company has a consensus rating of Buy and a consensus price target of $24.25.

NASDAQ:AQST traded down $0.07 during trading hours on Thursday, reaching $7.47. The company had a trading volume of 54,308 shares, compared to its average volume of 100,089. The company has a debt-to-equity ratio of 1.88, a quick ratio of 3.42 and a current ratio of 3.63. Aquestive Therapeutics has a twelve month low of $5.80 and a twelve month high of $20.70.

Aquestive Therapeutics (NASDAQ:AQST) last posted its quarterly earnings results on Tuesday, November 6th. The company reported ($0.64) EPS for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.15). The business had revenue of $13.27 million for the quarter, compared to analyst estimates of $14.75 million. Equities research analysts anticipate that Aquestive Therapeutics will post -1.15 earnings per share for the current year.

In related news, CFO John T. Maxwell acquired 10,000 shares of the firm’s stock in a transaction on Wednesday, November 21st. The stock was acquired at an average cost of $9.80 per share, for a total transaction of $98,000.00. The purchase was disclosed in a filing with the SEC, which is available at this link. Also, CEO Keith J. Kendall acquired 7,950 shares of the firm’s stock in a transaction on Friday, November 23rd. The stock was bought at an average price of $10.10 per share, with a total value of $80,295.00. The disclosure for this purchase can be found here. Insiders have purchased a total of 28,650 shares of company stock valued at $275,311 over the last quarter.

A number of hedge funds and other institutional investors have recently modified their holdings of AQST. Crestline Management LP bought a new position in Aquestive Therapeutics in the 3rd quarter worth $201,422,000. Perceptive Advisors LLC purchased a new stake in shares of Aquestive Therapeutics during the 3rd quarter valued at about $20,137,000. Alliancebernstein L.P. purchased a new stake in shares of Aquestive Therapeutics during the 3rd quarter valued at about $14,323,000. BlackRock Inc. purchased a new stake in shares of Aquestive Therapeutics during the 3rd quarter valued at about $8,254,000. Finally, Vanguard Group Inc purchased a new stake in shares of Aquestive Therapeutics during the 3rd quarter valued at about $8,055,000. Institutional investors and hedge funds own 64.49% of the company’s stock.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc, a specialty pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs. Its products are developed using its PharmFilm technology. The company's marketed products include Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Zuplenz, an oral soluble film formulation of ondansetron antagonist for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery.

Further Reading: How to Use the New Google Finance Tool

Get a free copy of the Zacks research report on Aquestive Therapeutics (AQST)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aquestive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquestive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply